文献速递炎症性肠病胃肠动力与功能性疾病

心理共病对炎症性肠病预后影响的纵向随访研究

Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-11

该纵向随访研究纳入218例处于生化缓解期(粪便钙卫蛋白<250 µg/g)的成人IBD患者,基线评估焦虑、抑郁和躯体化共病,随访至少2年。多因素Cox回归显示,随着心理共病数量增加,激素使用或疾病 flare、治疗升级及至少一个终点事件的风险显著升高。结论:基线心理共病负担越重,IBD疾病病程越差。

要点

  • 基线心理共病数量越多,IBD不良结局风险越高。
  • 三种心理共病者治疗升级风险显著增加(HR=8.19)。
  • 应关注IBD患者心理共病的筛查与干预。

核心结论

  • 处于生化缓解期的IBD患者,基线心理共病数量越多,后续疾病病程越差。

研究设计与样本

  • 纵向随访研究,纳入218例生化缓解(粪便钙卫蛋白<250 µg/g)的成人IBD患者,基线收集人口学、症状及心理共病(焦虑、抑郁、躯体化)数据,随访至少2年。

主要发现

  • 218例参与者中,48例(22.0%)有1种、13例(6.0%)有2种、9例(4.1%)有3种心理共病。
  • 有2种心理共病者激素处方或疾病 flare 的 HR=3.18(95%CI 1.44-7.02),治疗升级的 HR=2.48(95%CI 1.03-5.93)。
  • 有3种心理共病者激素处方或疾病 flare 的 HR=3.53(95%CI 1.26-9.92),治疗升级的 HR=8.19(95%CI 2.88-23.23)。
  • 至少发生一个终点事件的风险随心理共病数量增加而升高:1种 HR=1.74(95%CI 1.07-2.82),2种 HR=2.47(95%CI 1.12-5.46),3种 HR=4.93(95%CI 1.84-13.17)。

临床怎么用

  • 对IBD患者应评估焦虑、抑郁和躯体化等心理共病,心理负担重者可能需更密切监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psychological co-morbidity is more common in patients with inflammatory bowel disease (IBD), compared with the general population, but little is known about the cumulative effect of increasing psychological burden on disease behaviour. AIMS: To examine the effect of psychological co-morbidity on inflammatory bowel disease in a longitudinal follow-up study. METHODS: We collected complete demographic, symptom and psychological co-morbidity data (anxiety, depression and somatisation scores) at baseline from adults with IBD in biochemical remission (faecal calprotectin <250 µg/g). Objective markers of disease activity, including glucocorticosteroid prescription or flare of disease activity, escalation of therapy, hospitalisation or intestinal resection, were reviewed ≥2 years of follow-up. We performed multivariate Cox regression, controlling for patient characteristics and follow-up duration, to examine cumulative effect of psychological co-morbidities on subsequent IBD behaviour. RESULTS: Among 218 participants, 48 (22.0%) had one, 13 (6.0%) two and nine (4.1%) three psychological co-morbidities at baseline. Following multivariate Cox regression analysis, glucocorticosteroid prescription or flare, and escalation of medical therapy were significantly higher among those with two (hazard ratio [HR] = 3.18; 95% confidence interval [CI] 1.44-7.02, and HR = 2.48; 95% CI 1.03-5.93, respectively) or three (HR = 3.53; 95% CI 1.26-9.92, and HR = 8.19; 95% CI 2.88-23.23, respectively) psychological co-morbidities. Occurrence of at least one endpoint of interest was significantly higher with increasing psychological co-morbidity (HR = 1.74; 95% CI 1.07-2.82 for one, HR = 2.47; 95% CI 1.12-5.46 for two and HR = 4.93; 95% CI 1.84-13.17 for three psychological co-morbidities). CONCLUSIONS: Individuals with IBD in biochemical remission experienced a worse disease course with increasing psychological co-morbidity at baseline.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fairbrass KM, Gracie DJ, Ford AC, et al. Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. Aliment Pharmacol Ther. 2021. PMID: 34114664. doi:10.1111/apt.16454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。